{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:59:51Z","timestamp":1792598391130,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40487-024-00319-x","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T15:15:07Z","timestamp":1734362107000},"page":"11-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimizing Real-World Outcomes in High-Risk Relapsed\/Refractory (r\/r) DLBCL with CAR T Cell Therapy: A Vodcast and Case Example"],"prefix":"10.1007","volume":"13","author":[{"given":"Gloria","family":"Iacoboni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"P\u00e9rez Raya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"issue":"19","key":"319_CR1","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","volume":"4","author":"D Sermer","year":"2020","unstructured":"Sermer D, Batlevi C, Palomba ML, et al. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv. 2020;4(19):4669\u201378.","journal-title":"Blood Adv"},{"issue":"Suppl 3","key":"319_CR2","first-page":"21","volume":"10","author":"S Adkins","year":"2019","unstructured":"Adkins S. CAR T-cell therapy: adverse events and management. J Adv Pract Oncol. 2019;10(Suppl 3):21\u20138.","journal-title":"J Adv Pract Oncol"},{"issue":"1","key":"319_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","volume":"14","author":"A Trabolsi","year":"2024","unstructured":"Trabolsi A, Arumov A, Schatz JH. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J. 2024;14(1):27.","journal-title":"Blood Cancer J"},{"issue":"2","key":"319_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000186","volume":"3","author":"L Y\u00e1\u00f1ez","year":"2019","unstructured":"Y\u00e1\u00f1ez L, S\u00e1nchez-Escamilla M, Perales MA. CAR T cell toxicity: current management and future directions. HemaSphere. 2019;3(2): e186.","journal-title":"HemaSphere"},{"issue":"Suppl. 1","key":"319_CR5","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1182\/blood-2022-158822","volume":"140","author":"DJ Landsburg","year":"2022","unstructured":"Landsburg DJ, Frigault M, Heim M, et al. Real-world outcomes for patients with relapsed or refractory (R\/R) aggressive B-cell non-Hodgkin\u2019s lymphoma (aBNHL) treated with commercial tisagenlecleucel: subgroup analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Blood. 2022;140(Suppl. 1):1584\u20137.","journal-title":"Blood"},{"issue":"10","key":"319_CR6","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403\u201315.","journal-title":"Lancet Oncol"},{"issue":"10","key":"319_CR7","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1002\/cam4.3881","volume":"10","author":"G Iacoboni","year":"2021","unstructured":"Iacoboni G, Villacampa G, Martinez-Cibrian N, et al. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Med. 2021;10(10):3214\u201323.","journal-title":"Cancer Med"},{"issue":"22","key":"319_CR8","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton MP, Sugio T, Noordenbos T, et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N Engl J Med. 2024;390(22):2047\u201360.","journal-title":"N Engl J Med"},{"issue":"4","key":"319_CR9","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Fraietta JA, Gerson JN, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024;30(4):984\u20139.","journal-title":"Nat Med"},{"issue":"2","key":"319_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine BL, Pasquini MC, Connolly JE, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024;30(2):338\u201341.","journal-title":"Nat Med"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-024-00319-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-024-00319-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-024-00319-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T10:56:09Z","timestamp":1741085769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-024-00319-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1007\/s40487-024-00319-x","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gloria\u00a0Iacoboni: honoraria and\/or travel support from: Abbvie, AstraZeneca, Autolus, Bristol-Myers Squibb, Kite\/Gilead, Miltenyi, and Novartis. Mar\u00eda P\u00e9rez Raya: no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}